冠心病P2Y12基因多态性与氯吡格雷抵抗的相关性研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Correlative analysis between P2Y12 gene polymorphism and clopidogrel resistance in coronary heart disease 作者：王珣 ; 张远恒 ; 张弛 英文作者：Wang Xun;Zhang Yuanhen;Zhang Chi;Department of Cardiology,Wuhan Third Hospital;Department of Cardiology,Puren Hospital Affiliated to Wuhan University of Science and Technology; 关键词：冠心病 ; 血小板二磷酸腺苷受体亚基12 ; 基因多态性 ; 氯吡格雷抵抗 英文关键词：Coronary heart disease;;Platelet adenosine diphosphate receptor subunit 12;;Gene polymorphism;;Clopidogrel resistance 中文刊名：GZYI 英文刊名：Guizhou Medical Journal 机构：武汉市第三医院心内科;武汉科技大学附属普仁医院心内科; 出版日期：2019-01-24 出版单位：贵州医药 年：2019 期：v.43 基金：武汉市卫生局临床医学科研项目(编号:WX12D01) 语种：中文; 页：GZYI201901006 页数：3 CN：01 ISSN：52-1062/R 分类号：23-25

摘要

目的探讨冠心病患者血小板二磷酸腺苷(ADP)受体亚基12(P2Y12)基因G52T多态性位点与氯吡格雷抵抗的关系。方法选取300例冠心病介入治疗后采用氯吡格雷进行抗血小板治疗的患者作为研究对象,根据血小板聚集率分为氯吡格雷抵抗组(抵抗组)43例、非氯吡格雷抵抗组(非抵抗组)257例,探讨P2Y12基因G52T多态性位点与氯吡格雷抵抗的关系。结果抵抗组患者P2Y12基因G52T多态性中GT、TT显著高于非抵抗组,差异有统计学意义(P<0.05);抵抗组的等位基因频率T显著高于非抵抗组,差异有统计学意义(P<0.05)。P2Y12基因G52T位点GT、TT频率增高(P<0.05)、合并糖尿病是氯吡格雷抵抗的危险因素(P<0.05)。结论P2Y12基因G52T位点GT、TT频率增高会增加冠心病介入术后患者氯吡格雷抵抗的风险。
        Objective To investigate the relationship between G52 Tpolymorphism of platelet adenosine diphosphate(ADP)receptor subunit 12(P2Y12)gene and clopidogrel resistance in patients with coronary heart disease.Methods The total of 300 patients with coronary heart disease who underwent antiplatelet therapy was treated with clopidogrel as the study group.According to the platelet aggregation rate,43 patients were divided into clopidogrel resistance group(resistance group)and non-clopidogrel resistance group(257cases).The relationship between the polymorphism of P252 gene and clopidogrel was studied.Results The levels of GT and TT in the G52 Tpolymorphism of the P2Y12 gene were significantly higher in the RC group than in the non-resistant group(P<0.05).The allele frequency T in the resistance group was significantly higher than that in the non-resistant group(P<0.05).The risk factor of clopidogrel resistance in the G52 Tlocus of P2Y12gene(P<0.05).ConclusionIncreased frequency of GT and TT in the G52 Tsite of P2Y12 gene increased the risk of clopidogrel resistance in patients with coronary heart disease after intervention.

引文

[1] Ou W,He Y,Li A,et al.Genotype frequencies of CYP2C19,P2Y12and GPIIIa polymorphisms in coronary heart disease patients of han ethnicity,and their impact on clopidogrel responsiveness[J].Int Heart J,2016,57(5):586-592.
    [2] Alfredsson J,Lindahl TL,Gustafsson KM,et al.Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel[J].Thromb Res,2015,136(2):335-340.
    [3]赖胜荣,刘俊.药物基因组学与抗血小板药物抵抗研究进展[J].药学与临床研究,2014,22(2):155-157.
    [4]贺军,张艳红,苟志平,等.冠心病介入术后氯吡格雷抵抗的代谢相关基因检测及临床对策研究[J].中国医师杂志,2015,17(7):1019-1023.
    [5]顾永丽,孙增先.阿司匹林抵抗与氯吡格雷抵抗的研究进展[J].中国医院药学杂志,2016,36(10):866-869.
    [6] Yang H,Chen Y,Gao C.Associations of P2Y12Rgene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel[J].Cardiovasc Ther,2016,34(6):460-467.
    [7] Wang SH,Li X,Hou FL,et al.Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease[J].Genet Mol Res,2016,15(2):90-93.
    [8]王涛.血小板膜受体P2Y12基因多态性与冠心病患者氯吡格雷抵抗的相关性研究[J].中西医结合心脑血管病杂志,2015,13(3):353-356.
    [9]王宝祥,李焰生.阿司匹林和氯吡格雷抵抗相关的遗传学机制研究[J].中华老年心脑血管病杂志,2014,16(9):1002-1003.
    [10]刘利龙,宋佳,吴禹蒙,等.P2Y12基因多态性与氯吡格雷抵抗的相关性研究[J].中国药房,2014,25(32):3065-3068.
    [11]李晓静,陈晓敏.血小板P2Y12受体基因多态性与氯吡格雷抵抗相关性研究[J].浙江大学学报:医学版,2014(3):333-338.
    [12]邹晓,范利,曹剑.基因多态性与氯吡格雷抵抗相关性的研究进展[J].中华保健医学杂志,2015,17(01):68-71.
    [13]张文斌,张新霞,陈晓燕,等.P2Y12基因多态性与冠心病患者氯吡格雷抵抗的相关性研究[J].中国心血管杂志,2015,20(1):18-22.
    [14]邢元,李为民.氯吡格雷抵抗中基因多态性研究进展[J].国际心血管病杂志,2014,41(02):91-94.
    [15]吴小利,李健,王成彬.氯吡格雷抵抗患者的血小板功能的实验室监测和遗传基因多态性的研究进展[J].临床检验杂志(电子版),2014(02):595-602.